NEW YORK, Feb. 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN).Shareholders who purchased shares of AZN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/astrazeneca-plc-loss-submission-form-2/?id=127838&from=4 CLASS PERIOD: February 23, 2022 to ...

NEW YORK, Feb. 09, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and December 17, 2024, both dates inclusive (the “Class Period”), of the February 21, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased AstraZeneca securities during the Class Period you may be entitled to compensation without payment of any out of pocket fe ...

NEW YORK, Feb. 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AstraZeneca investors who were adversely affected by alleged securities fraud between February 23, 2022 and December 17, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/astrazeneca-plc-lawsuit- ...

A fresh earnings release was the news development powering AstraZeneca's (AZN 2.01%) share price higher on Thursday. Investors were clearly impressed by the pharmaceutical company's numbers, as the stock closed the day more than 2% higher in value. This was notably better than the 0.4% bump of the S&P 500 index.A crushing bottom-line beatAstraZeneca unveiled both its fourth-quarter and full-year 2024 results before market open today, revealing that its total revenue was $14.89 billion. This represented a me ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased AstraZeneca PLC securities between February 23, 2022, and December 17, 2024, about the upcoming lead plaintiff deadline for a securities class action lawsuit [1] Group 1: Class Action Details - Investors who purchased AstraZeneca securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must file with the Court by February 21, 2025 [3] - The lawsuit alleges that AstraZeneca made materially false and misleading statements regarding its business operations and legal risks, particularly related to insurance fraud in China [5] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has been ranked highly for its performance in securities class action settlements [4]

AstraZeneca’s (AZN) fourth-quarter 2024 core earnings of $1.05 per American depositary share (“ADS”) missed the Zacks Consensus Estimate of $1.07. Core earnings of $2.09 per share rose 44% year over year on a reported basis and 49% at constant exchange rates (“CER”).Total revenues of $14.89 billion rose 24% on a reported basis and 25% at CER, driven by higher product sales and alliance revenues from partnered medicines. Revenues beat the Zacks Consensus Estimate of $14.28 billion.All growth rates mentioned ...

Financial Data and Key Metrics Changes - Total revenue for 2024 increased by 21%, with a core EPS growth of 19% [3][19] - Core operating expenses rose by 14%, indicating effective cost management relative to revenue growth [3][21] - Product sales grew by 19% for the full year, driven by strong demand across regions [19] Business Line Data and Key Metrics Changes - Oncology revenues reached $22.4 billion, a 24% increase, with Tagrisso surpassing $6.5 billion in sales [34] - BioPharmaceuticals revenue grew by 21% to $21.9 billion, with respiratory and immunology products showing strong performance [56] - Rare disease revenue increased by 16% to $8.8 billion, driven by demand and new market launches [74] Market Data and Key Metrics Changes - China revenue grew by 11% overall in 2024, despite a 3% decline in Q4 due to hospital ordering dynamics [10][11] - Emerging markets saw a growth of 22%, highlighting significant unmet medical needs [12] - The inhaled market in China experienced a slowdown, with Q4 growth at 9% compared to 23% in Q3 [105] Company Strategy and Development Direction - The company aims to deliver 20 new medicines by 2030, with eight already approved [5][87] - Investments are being made in manufacturing capabilities and transformative technologies to support long-term growth [32][86] - The company is focused on achieving $80 billion in total revenue by 2030, with ongoing high-value trial readouts expected to drive growth [84][87] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential in emerging markets, particularly in China, despite current headwinds [14][108] - The company anticipates continued strong performance in 2025, with total revenue expected to increase by a high single-digit percentage [27] - Management acknowledged challenges from VBP inclusion in China but remains optimistic about overall portfolio growth [108] Other Important Information - The company is facing ongoing investigations in China related to unpaid importation taxes, with potential fines if found liable [6][10] - Significant investments are being made in next-generation manufacturing capabilities and technology to support future growth [32][30] Q&A Session Summary Question: Insights on China revenue dynamics - The revenue in Q4 declined by 3%, primarily due to hospital inventory management and a mild winter affecting respiratory product demand [10][11][102] - Management noted that the respiratory portfolio is expected to perform better as flu infections rise in early 2025 [104][108] Question: Guidance assumptions for China - The guidance for 2025 considers potential declines in China due to VBP inclusion for certain products, but overall growth is still anticipated [92][108] Question: Investigations and potential fines - The company disclosed a potential liability related to investigations, with fines possibly ranging from 1 to 5 times the amount of avoided import duties [95][96]

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? The Z ...

Full Year and Q4 2024 Results Conference call and webcast for investors and analysts 06 February 2025 Forward-looking statements This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statemen ...

Core Insights - AstraZeneca reported revenue of $14.89 billion for the quarter ended December 2024, reflecting a 23.8% increase year-over-year and a surprise of +4.26% over the Zacks Consensus Estimate of $14.28 billion [1] - The earnings per share (EPS) for the quarter was $1.05, compared to $0.73 in the same quarter last year, although it fell short of the consensus EPS estimate of $1.07 by -1.87% [1] Financial Performance Metrics - AstraZeneca's stock has returned +6.5% over the past month, outperforming the Zacks S&P 500 composite's +2.1% change, and currently holds a Zacks Rank 3 (Hold) [3] - Key product performance includes: - Symbicort in the U.S. generated $299 million, exceeding the average estimate of $235.06 million [4] - Oncology product Tagrisso in the U.S. reported $767 million, surpassing the estimated $709.65 million [4] - Collaboration revenue totaled $815 million, significantly above the average estimate of $419.12 million, marking a +68.4% change year-over-year [4] - Oncology product Tagrisso worldwide achieved $1.70 billion, compared to the estimated $1.68 billion, representing a +20% increase year-over-year [4] - BioPharmaceuticals product Farxiga worldwide reported $1.93 billion, slightly below the estimate of $1.96 billion, but still showing a +20.4% year-over-year change [4]